Gene expression and pain
AssigneeAdynxx, Inc.
InventorJulien MAMET
Life of this patent
Estimating the term…
Abstract
The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.
Claims21
An oligonucleotide decoy comprising two transcription factor binding sites, wherein each transcription factor binding site binds to a transcription factor selected from the group consisting of POU1F1, POU2F, POU3F, POU5F1, USF, EGR1, CREB/ATF, AP1, CEBP, SRF, ETS1, MEF2, SP1, RUNX, NFAT, ELK1, ternary complex factors, STAT, GATA1, ELF1, nuclear factor-granulocyte/macrophage a, POU4F1, HNF1, ZFHX3, IRF, TEAD1, TBP, NFY, caccc-box binding factors, KLF4, KLF7, IKZF, MAF, REST, HSF, KCNIP3 and PPAR transcription factors.
An oligonucleotide decoy, comprising:
- (a) a sequence selected from the group consisting of SEQ ID NOs.:
- 1-40, 42, 45 and 47-53;
- (b) a sequence having at least 90% identity with a sequence selected from the group consisting of SEQ ID NOs.:
- 1-39, 42, 45, and 47-53;
- (c) a sequence having at least 85% identity with a sequence selected from the group consisting of SEQ ID NOs.:
- 1-17, 19-39, 42, 45 47-53;
- or
- (d) a sequence having at least 80% identity with a sequence selected from the group consisting of SEQ ID NOs.:
- 1-5, 7-17, 19-39, 42, 45 and 47-53.
The method of claim 17, wherein the cell is a neuron.
The method of claim 17, wherein modulation of transcription suppresses, inhibits, activates, induces or stabilizes gene expression.
The method of claim 17, wherein said gene is selected from the group consisting of BDKRD2, HTR3A, SCN9A, BDNF, GRM5, NOS1, GCH1, CDK5R1, and PNMT.
A method for treating or preventing pain in a patient comprising administering to the patient a therapeutically effective amount of one or more oligonucleotide decoys, wherein each oligonucleotide decoy comprises a transcription factor binding site, and wherein said transcription factor binding site binds to a transcription factor selected from the group consisting of POU1F1, POU2F, POU3F, POU5F1, USF, EGR1, CREB/ATF, CEBP, SRF, MEF2, SP1, RUNX, NFAT, ELK1, ternary complex factors, ELF1, nuclear factor-granulocyte/macrophage a, POU4F1, HNF1, ZFHX3, IRF, TEAD1, TBP, NFY, caccc-box binding factors, KLF4, KLF7, IKZF, MAF, REST, HSF, KCNIP3 and PPAR.
Dependencies are inferred from the claim text.